Evaluation of Sinonasal Outcome Test (SNOT-22) Domains in the Assessment of the Quality of Life in Patients with Nasopharyngeal Carcinoma.
SNOT-22
chronic rhinosinusitis
nasopharyngeal carcinoma
psychometrics
quality of life
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2023
2023
Historique:
received:
03
05
2023
accepted:
04
07
2023
medline:
24
7
2023
pubmed:
24
7
2023
entrez:
24
7
2023
Statut:
epublish
Résumé
Few instruments are available for assessing the otorhinologic-related quality of life (QOL) in nasopharyngeal carcinoma (NPC) patients. Therefore, we evaluated whether the 22-item Sinonasal Outcome Test (SNOT-22) could be applied to these patients. Patients diagnosed with NPC, who had been treated with standard protocol and followed up in our institute between 2019 and 2022, were invited to join the cross-sectional study during their clinic visits. All participants completed the SNOT-22 and Eustachian Tube Dysfunction Questionnaire-7 once they were recruited. Confirmatory factor analysis (CFA) was performed to decide the most suitable model for the underlying SNOT-22 subdomains, along with various validity and reliability tests. We identified a total of 275 patients, with 84 (30.5%) women and 191 (69.5%) men. The mean age was 54.1 years (standard deviation: 11.2). Among these patients, 171 (62.1%) were in late stages, and 260 (94.5%) received chemoradiotherapy as treatment. The median interval between primary RT treatment and questionnaire completion was 50 months (interquartile range: 29-93). CFA supported a five-factor model for the SNOT-22 for NPC patients, including nasal, ear/facial, sleep, function, and emotion domains. The internal consistency and test-retest reliability of the SNOT-22 domain score were good. In addition, known-group validity was good for the SNOT-22 total score and domain scores according to the disease recurrence status. Psychometric analyses supported the reliability and validity of a five-domain SNOT-22 for assessing otorhinologic-related QOL in NPC patients.
Sections du résumé
Background
UNASSIGNED
Few instruments are available for assessing the otorhinologic-related quality of life (QOL) in nasopharyngeal carcinoma (NPC) patients. Therefore, we evaluated whether the 22-item Sinonasal Outcome Test (SNOT-22) could be applied to these patients.
Methods
UNASSIGNED
Patients diagnosed with NPC, who had been treated with standard protocol and followed up in our institute between 2019 and 2022, were invited to join the cross-sectional study during their clinic visits. All participants completed the SNOT-22 and Eustachian Tube Dysfunction Questionnaire-7 once they were recruited. Confirmatory factor analysis (CFA) was performed to decide the most suitable model for the underlying SNOT-22 subdomains, along with various validity and reliability tests.
Results
UNASSIGNED
We identified a total of 275 patients, with 84 (30.5%) women and 191 (69.5%) men. The mean age was 54.1 years (standard deviation: 11.2). Among these patients, 171 (62.1%) were in late stages, and 260 (94.5%) received chemoradiotherapy as treatment. The median interval between primary RT treatment and questionnaire completion was 50 months (interquartile range: 29-93). CFA supported a five-factor model for the SNOT-22 for NPC patients, including nasal, ear/facial, sleep, function, and emotion domains. The internal consistency and test-retest reliability of the SNOT-22 domain score were good. In addition, known-group validity was good for the SNOT-22 total score and domain scores according to the disease recurrence status.
Conclusion
UNASSIGNED
Psychometric analyses supported the reliability and validity of a five-domain SNOT-22 for assessing otorhinologic-related QOL in NPC patients.
Identifiants
pubmed: 37485039
doi: 10.2147/CMAR.S416353
pii: 416353
pmc: PMC10362877
doi:
Types de publication
Journal Article
Langues
eng
Pagination
719-728Informations de copyright
© 2023 Wu et al.
Déclaration de conflit d'intérêts
None of the authors has any conflict of interest.
Références
Lancet. 2019 Jul 6;394(10192):64-80
pubmed: 31178151
Int Forum Allergy Rhinol. 2012 Mar-Apr;2(2):174-81
pubmed: 22253093
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Eur Arch Otorhinolaryngol. 2016 Feb;273(2):471-7
pubmed: 25634060
Laryngoscope. 2001 Apr;111(4 Pt 1):669-80
pubmed: 11359139
Qual Life Res. 2013 May;22(4):715-23
pubmed: 22669472
Am J Rhinol Allergy. 2015 Mar-Apr;29(2):100-5
pubmed: 25785749
Expert Rev Anticancer Ther. 2015 Jan;15(1):109-19
pubmed: 25231774
Cancer. 2012 Aug 1;118(15):3710-8
pubmed: 22180127
Laryngoscope. 2022 May;132(5):933-941
pubmed: 34437720
Head Neck. 2020 Nov;42(11):3243-3252
pubmed: 33463843
Laryngoscope. 2012 May;122(5):1137-41
pubmed: 22374681
Int Forum Allergy Rhinol. 2016 Sep;6(9):914-20
pubmed: 27279464
Turk J Emerg Med. 2018 Aug 07;18(3):91-93
pubmed: 30191186
Health Qual Life Outcomes. 2016 Sep 05;14(1):123
pubmed: 27595602
JAMA Otolaryngol Head Neck Surg. 2014 Aug;140(8):712-9
pubmed: 25074504
Front Psychol. 2016 May 26;7:769
pubmed: 27303333
Health Qual Life Outcomes. 2016 May 10;14:76
pubmed: 27164979
Cancers (Basel). 2020 Jun 12;12(6):
pubmed: 32545461
J Clin Oncol. 1999 Mar;17(3):1008-19
pubmed: 10071296
Clin Otolaryngol. 2009 Oct;34(5):447-54
pubmed: 19793277
Qual Life Res. 2003 Feb;12(1):93-8
pubmed: 12625522
Int Forum Allergy Rhinol. 2017 Dec;7(12):1140-1148
pubmed: 29028287
Front Oncol. 2020 Apr 17;10:437
pubmed: 32363158
Eur Arch Otorhinolaryngol. 1992;249(4):206-8
pubmed: 1642877
Cancer. 2002 Feb 15;94(4):1012-7
pubmed: 11920470
Int Forum Allergy Rhinol. 2017 Nov;7(11):1045-1051
pubmed: 28806502
Head Neck. 2009 Jun;31(6):738-47
pubmed: 19260135
Cancers (Basel). 2021 Oct 10;13(20):
pubmed: 34680211